lxe408
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2022 (NCT05593666)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- LeishmaniaINHIBITOR
Leishmania inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997159 | Phase 2 | Nov 16, 2025 | Drugs for Neglected Diseases Initiative, Novartis |
| NCT06632600 | Phase 2 | Aug 8, 2025 | Novartis |
| NCT05957978 | Phase 2 | Jan 31, 2024 | Drugs for Neglected Diseases Initiative, Novartis, University of Gondar |
| NCT05593666 | Phase 2 | Nov 7, 2022 | Drugs for Neglected Diseases Initiative, Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 1 | 1 | 2022 |
| Drugs for Neglected Diseases Initiative | Academic/Hospital | 3 | 3 | 1 | 2022 |
| University of Gondar | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1